Singapore, March 11 -- Switzerland-based Curatis Holding AG and Neupharma, a Japanese pharmaceutical company specialising in oncology, immunology, pulmonology and cardiology disorders, have announced an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan.

Under the terms of the agreement, Neupharma will receive exclusive rights to develop and commercialise corticorelin for the treatment of peritumoral brain edema (PTBE) in Japan. PTBE is a tumour-associated condition for which no approved targeted therapies currently exist.

Neupharma will finance and conduct a pivotal clinical trial in Japan to support filing for approval in Japan. Curatis will receive upfront and milestone payments for the achievement of r...